|
© 2007 American Academy of Neurology Cortical biochemistry in MCI and Alzheimer diseaseLack of correlation with clinical diagnosisFrom the Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine (M.S.F., S.J., S.L., V.M.-Y.L., J.Q.T.), Institute on Aging (M.S., V.M.-Y.L., J.Q.T.), and Department of Pharmacology (D.P.), University of Pennsylvania School of Medicine, Philadelphia, PA; and Department of Neurological Sciences (E.J.M., S.L.), Rush University Medical Center, Chicago, IL. Address correspondence and reprint requests to Dr. Mark S. Forman, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 422 Curie Blvd., 605B Stellar-Chance Building, Philadelphia, PA 19104; e-mail: formanm{at}mail.med.upenn.edu Objective: Mild cognitive impairment, hypothesized to be prodromal Alzheimer disease (AD), shows abundant senile plaques and neurofibrillary tangles, but its biochemical correlates remain undefined.
Methods: Biochemical profiles of Aß, tau,
Results: Insoluble Aß and tau, as well as tissue isoprostanes, from each brain region analyzed did not correlate with the clinical diagnosis proximate to death, but insoluble Aß and 8,12-iso-iPF2 Conclusions: The biochemical alterations in cortical tau, Aß, and isoprostane do not reflect the onset of clinical dementia.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the March 6 issue to find the title link for this article. Supported by grants from the NIH (P01 AG14449, P30 AG10161, RO1 AG10688, PO1 AG09466, and K08 AG20073). Disclosure: The authors report no conflicts of interest. Received March 8, 2006. Accepted in final form November 8, 2006.
This article has been cited by other articles:
|
||||||||||||||||||||||||